A PHASE II OPEN LABEL, MULTI-CENTER CLINICAL TRIAL TO EVALUATE SAFETY AND EFFICACY OF ORAL WCK 2349 (1000 mg BID and 1200 mg BID) IN THE TREATMENT OF COMPLICATED SKIN AND SOFT TISSUE INFECTIONS CAUSED BY GRAM POSITIVE BACTERIA, INCLUDING METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS.
Latest Information Update: 30 Aug 2016
At a glance
- Drugs Alalevonadifloxacin (Primary)
- Indications Gram-positive infections; Methicillin-resistant Staphylococcus aureus infections; Skin and soft tissue infections
- Focus Therapeutic Use
- 04 Nov 2011 New trial record